Increased survival of tumor-bearing mice by the delta opioid SNC 80

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4563-4567

  Gomez Flores, Ricardo ^a,d   Caballero Hernández, Diana ^a   Tamez Guerra, Reyes ^a   Rodríguez Padilla, Cristina ^a   Tamez Guerra, Patricia ^a   Rice, Kenner C ^b   Hicks, Mary E ^c   Weber, Richard J ^c  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d NONE   (Mexico)

Author keywords

L5178y R Lymphoma; Murine tumor cells; Non peptide opioids; SNC 80; Tumor mouse model; opioid agonist

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; DELTA OPIATE RECEPTOR AGONIST;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; GROWTH INHIBITION; IMMUNOPOTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR VOLUME;

EID: 28444473761     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Brown R: Heroin dependence. Wis Med J 103: 20-26, 2004.
2. Wright D, Gfroerer J and Epstein J: The use of external data sources and ratio estimation to improve estimates of hardcore drug use from the NHSDA. NIDA Res Monogr 167: 477-497, 1997.
3. Stein C: Peripheral mechanisms of opioid analgesia. Anesth Analg 76: 182-191, 1993.
4. Weber RJ and Pert A: The periaqueductal gray matter mediates opiate-induced immunosuppression. Science 245: 188-190, 1989.
5. Gomez-Flores R and Weber R: Opioids, opioid receptors, and the immune system. In: Cytokines-stress and Immunity. Plotnikoff NP, Faith RE, Murgo AJ, Good RA (eds.). Boca Raton, CRC Press, pp. 281-314, 1999.
6. Rogers TJ, Taub DD, Eisenstein TK, Geller EB and Adler MW: Immunomodulatory activity of kappa-, mu-, and delta-selective opioid compounds. NIDA Res Monogr 105: 82-88, 1991.
7. House RV, Thomas PT, Kozak JT and Bhargava HN: Suppression of immune function by non-peptidic delta OR antagonists. Neurosci Lett 198: 119-122, 1995.
8. Shavit Y, Terman GW, Martin FA, Lewis JW, Liebeskind JC et al: Stress, opioid peptides, the immune system, and cancer. J Immunol 135: 834s-837s, 1985.
9. Carpenter GW, Garza HH Jr, Gebhardt BM and Carr DJ: Chronic morphine treatment suppresses CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen. Brain Behav Immun 8: 185-203, 1994.
10. Zagon IS and McLaughlin PJ: Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37: 79-88, 2003.
11. Kawase M, Sakagami H, Furuya K, Kikuchi H, Nishikawa H, Motohashi N, Morimoto Y, Varga A and Molnar J: Cell death-inducing activity of opiates in human oral tumor cell lines. Anticancer Res 22: 211-214, 2002.
12. Yeager MP and Colacchio TA: Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 126: 454-456, 1991.
13. Bonn D: Morphine stimulates tumour growth. Lancet Oncol 3: 520, 2002.
14. Sergeeva MG, Grishina ZV and Varfolomoyev SD: Morphine effect on proliferation of normal and tumor cells of immune origin. Immunol Lett 36: 215-218, 1993.
15. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY et al: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62: 4491-4498, 2002.
16. Gomez-Flores R, Rodriguez-Padilla C, Mehta RT, Galan-Wong L, Mendoza-Gamboa E and Tamez-Guerra R: Nitric oxide and TNF-alpha production by murine peritoneal macrophages activated with a novel 20-kDa protein isolated from Bacillus thuringiensis var. thuringiensis parasporal bodies. J Immunol 158: 3796-3799, 1997.
17. Gomez-Flores R and Weber RJ: Increased nitric oxide and TNF-α production by rat macrophages following in vitro stimulation and intravenous administration of SNC 80. Life Sci 68: 2675-2684, 2001.
18. Nowak JE, Gomez-Flores R, Calderon SN, Rice KC and Weber RJ: Rat NK cell, T cell, and macrophage functions following intracerebroventricular injection of SNC 80. J Pharmacol Exp Ther 286: 931-937, 1998.
19. Conti A: Oncology in neuroimmunomodulation. What progress has been made? Ann NY Acad Sci 917: 68-83, 2000.
20. Pacifici R, Di Carlo S, Bacosi A and Zuccaro P: Macrophage functions in drugs of abuse-treated mice. Int J Immunopharmacol 15: 711-716, 1993.
21. Cameron DJ: Effect of neuropeptides on macrophage mediated cytotoxicity in normal donors and cancer patients. Jpn J Exp Med 57: 31-39, 1987.
22. Hagi K, Uno K, Inaba K and Muramatsu S: Augmenting effect of opioid peptides on murine macrophage activation. J Neuroimmunol 50: 71-76, 1994.
23. Murgo AJ, Faith RE and Plotnikoff NP: Neuropeptides, cytokines, and cancer, interrelationships. In: Cytokines-Stress and Immunity. Plotnikoff NP, Faith RE, Murgo AJ, Good RA, (eds.). Boca Raton, CRC Press, pp. 133-160, 1999.
24. Suzuki S, Chuang LF, Doi RH, Bidlack JM and Chuang RY: Kappa-opioid receptors on lymphocytes of a human lymphocytic cell line: morphine-induced up-regulation as evidenced by competitive RT-PCR and indirect immunofluorescence. Int Immunopharmacol 1: 1733-1742, 2001.
25. Buchner RR, Vogen SM, Fischer W, Thoman ML, Sanderson SD et al: Anti-human kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide kappa R(33-52) derived from the predicted amino terminal region of the human kappa receptor. J Immunol 158: 1670-1680, 1997.
26. Blishchenko EY, Mernenko OA, Mirkina II, Satpaev DK, Ivanov VS et al: Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin beta-chain. Peptides 18: 79-85, 1997.
27. Iuvone T, Capasso A, D'Acquisto F and Carnuccio R: Opioids inhibit the induction of nitric oxide synthase in J774 macrophages. Biochem Biophys Res Commun 212: 975-980, 1995.
28. Ordaz-Sánchez I, Weber RJ, Rice KC, Zhang X, Rodríguez- Padilla C et al: Chemotaxis of human and rat leukocytes by the delta-selective non-peptidic opioid SNC 80. Rev Latinoamer Microbiol 45: 14-23, 2003.
29. Caballero-Hernandez D, Weber RJ, Hicks ME, Tamez-Guerra R, Rodriguez-Padilla C, Tamez-Guerra P, Rice KC, Ananthan S and Gomez-Flores R: 2005. Potentiation of rat lymphocyte proliferation by novel non-peptidic synthetic opioids. Int Immunopharmacol 5: 1271-1278, 2005.
30. Calderon SN, Rice KC, Rothman RB, Porreca F, Flippen-Anderson JL, Kayakiri H et al: Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist(+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl) -methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands. J Med Chem 40: 695-704, 1997.
31. Negus SS, Gatch MB, Mello NK, Zhang X and Rice K: Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J Pharmacol Exp Ther 286: 362-375, 1998.
32. Hicks ME, Gomez-Flores R, Wang C, Mosberg H and Weber RJ: Differential effects of the novel non-peptidic opioid 4-tyrosylamido-6-benzyl-1,2,3,4 tetrahydroquinoline (CGPM-9) on in vitro T lymphocyte and macrophage functions. Life Sci 68: 2685-2694, 2001.
33. Klimp AH, de Vries EG, Scherphof GL and Daemen T: A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol/Hematol 44: 143-161, 2002.
34. Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y et al: Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res 60: 6416-6420, 2000.
35. Gately MK and Brunda MJ: The potential of interleukin-12 for use in cancer therapy. Jpn J Cancer Chemother 23: 961-971, 1996.
36. Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E et al: Macrophages orchestrate the immune response to tumor cell death. Cancer Res 61: 7240-7247, 2001.